Safety and Efficacy of VDPHL01 in Males With AGA
Public ClinicalTrials.gov record NCT06972264. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Study identification
- NCT ID
- NCT06972264
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 480 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 11, 2025 (Actual)
- Primary completion
- Dec 2026 (Estimated)
- Completion
- Jul 2027 (Estimated)
- Last update posted
- Feb 12, 2026
2025 – 2027
United States locations
- U.S. sites
- 44
- U.S. states
- 22
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 73 | Birmingham | Alabama | 35209 | — |
| Site 89 | Birmingham | Alabama | 35244 | — |
| Site 77 | Phoenix | Arizona | 85006 | — |
| Site 69 | Encino | California | 91436 | — |
| Site 64 | Manhattan Beach | California | 90266 | — |
| Site 93 | Northridge | California | 91324 | — |
| Site 66 | Santa Monica | California | 90404 | — |
| Site 94 | Thousand Oaks | California | 91320 | — |
| Site 71 | Boca Raton | Florida | 33486 | — |
| Site 86 | Coral Gables | Florida | 33134 | — |
| Site 62 | Coral Gables | Florida | 33146 | — |
| Site 99 | Miami | Florida | 33173 | — |
| Site 54 | Ocala | Florida | 34470 | — |
| Site 96 | Tamarac | Florida | 33321 | — |
| Site 90 | Sandy Springs | Georgia | 30328 | — |
| Site 61 | Chicago | Illinois | 60611 | — |
| Site 53 | Clarksville | Indiana | 47129 | — |
| Site 55 | Plainfield | Indiana | 46168 | — |
| Site 79 | Leawood | Kansas | 66211 | — |
| Site 52 | Louisville | Kentucky | 40241 | — |
| Site 75 | New Orleans | Louisiana | 70124 | — |
| Site 84 | Glenn Dale | Maryland | 20769 | — |
| Site 87 | Rockville | Maryland | 20850 | — |
| Site 80 | Chestnut Hill | Massachusetts | 02467 | — |
| Site 59 | Quincy | Massachusetts | 02169 | — |
| Site 68 | Clinton Township | Michigan | 48038 | — |
| Site 83 | Troy | Michigan | 48084 | — |
| Site 82 | Hickory | North Carolina | 28602 | — |
| Site 92 | Huntersville | North Carolina | 28078 | — |
| Site 72 | Cincinnati | Ohio | 45236 | — |
| Site 57 | Portland | Oregon | 97210 | — |
| Site 81 | East Greenwich | Rhode Island | 02818 | — |
| Site 60 | Anderson | South Carolina | 29625 | — |
| Site 95 | Hermitage | Tennessee | 37076 | — |
| Site 76 | Austin | Texas | 78746 | — |
| Site 51 | Austin | Texas | 78759 | — |
| Site 74 | College Station | Texas | 77845 | — |
| Site 67 | Dallas | Texas | 75230 | — |
| Site 78 | Plano | Texas | 75024 | — |
| Site 88 | San Antonio | Texas | 78218 | — |
| Site 91 | Sugarland | Texas | 77479 | — |
| Site 63 | Norfolk | Virginia | 23502 | — |
| Site 85 | Norfolk | Virginia | 23502 | — |
| Site 70 | Mill Creek | Washington | 98012 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06972264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2026 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06972264 live on ClinicalTrials.gov.